Articles

A new technique which was found to improve surgical results for trabeculectomy

Technology is an essential tool for diagnostic, prognostic approaches to AMD management

HM Revenue & Customs (HMRC) has a Super Podcast, to alert ophthalmic businesses to major changes in the way they file and pay VAT, PAYE and corporation tax.

What is it and how might we avoid it?

An overview of the latest natural products found to be beneficial for preventing and treating AMD was provided by Dr Bernstein during retina subspecialty day at the annual meeting of the American Academy of Ophthalmology.

Procedure addresses challenges of leaking incisions and anterior chamber instability

Preferential hyperacuity perimetry testing is sensitive and helpful for early detection

Is monovision in your armamentarium?

Surgeons can now consider new treatment possibilities for patients that otherwise would have had limited options

Non-invasive techniques may detect signs of drug-induced toxicity at a pre-clinical stage

FAF imaging is a powerful and versatile tool that can be used to diagnose and monitor a number of retinal diseases, most of which are still largely under-diagnosed and therefore under-treated.

Highlights from an expert roundtable meeting

An intraocular device is a new concept in the treatment of AMD that taps into telescopic mirror technology to redesign patients' vision

Dennis S.C. Lam, MD, of Hong Kong and Stefan Seregard, MD, of Sweden have been appointed to serve a one-year term on the American Academy of Ophthalmology's (AAO) Board of Trustees.

Dr Bryan Lee, JD is a second-year resident at the Wilmer Eye Institute. He gives the Opthalmology Times Group his take on the recent AAO meeting.

Used for the treatment of blepharitis, AZASITE (azitthromycin ophthalmic solution) from Inspire Pharmaceuticals Inc., was used in two clinical trials in patients with anterior blepharitis. One trial had a two-week treatment period, the other trial a four-week treatment period.

In results due to be presented at the ARVO meeting in May Retina Implant says its first human clinical trial has exceeded its expectations with some patients able to see objects and shapes so clearly they were able to combine letters to form words and recognize foreign objects.

Santen Pharmaceutical Co., Ltd., the Japanes ophthalmic pharmaceutical company, has announced that Adrienne Graves, PhD, president and chief executive officer (CEO) of its wholly-owned US subsidiary, Santen Inc., has resigned...

The largest international ophthalmology congress, the World Ophthalmology Congress 2010 (WOC® 2010) will be held in Berlin from 5 ? 9 June 2010.

Former executives of Schering-Plough, Fred Hassan and Brent Saunders, have taken over the helm at Bausch & Lomb as chairman and CEO respectively.

LEEDS, England -- Ultralase, the vision correction specialist, presented its first set of results for a new treatment, Ultraelite, at the recent Winter meeting of the European Society of Cataract and Refractive Surgeons in Budapest.

One year post-surgery, patients who underwent Descemet's stripping automated endothelial keratoplasty (DSAEK) experienced greater cell loss overall compared to those who underwent penetrating keratoplasty (PKP), according to a new analysis of data collected from the Cornea Donor Study (CDS) Investigator Group's 2008 Specular Microscopy Ancillary Study (SMAS).

Dr Ludwin Monz is now the new CEO of Carl Zeiss Meditec, having taken over from Dr Michael Kaschke. Kaschke has been elected back to the Supervisory Board and was appointed its Chairman in a subsequent Supervisory Board meeting.

Last year a human trial involving administering gene therapy to Leber's congenital amaurosis (LCA) patients produced improvements in 12 children and young adults. The same researchers then conducted an animal study that found that a second injection into the previously untreated eye, was safe and effective with no signs of interference from immune reactions from the earlier injection.

Glaucoma remains the world's leading cause of irreversible blindness, but 50% of people who have this devastating disease don't know it,” said Dr Clive Midgal, president of the European Glaucoma Society.

The Congress of the French Ophthalmology Society, SFO, will take place at the Palais des Congres, 2 place de la Porte Maillot, Paris, France, 8-11 May 2010.

New research is emerging from the Vanderbilt Eye Institute that indicates the first sign of injury in glaucoma occurs in the brain.

A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116.

Practices look to the future wit htechnology that integrates scheduling, electronic records and filing

Ophthalmic viscosurgical devices are designed to facilitate safety and control during phacoemulsification. But not all OVDs are created equal...